|
|
Office Locations:
|
3380 Chastain Meadows Pkwy NW, Suite 200
Kennesaw, GA 30144
Phone: 800-227-2345
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
BrightEdge is the Philanthropic Impact Fund of the American Cancer Society (ACS). The firm's goal is to invest in companies that accelerate access to lifesaving technologies for the patients and families ACS serves. BrightEdge will accelerate the ACS mission while creating a sustainable funding source into the next century. BrightEdge raises capital from Impact Donors who want to have a more direct approach to philanthropy. BrightEdge invests in for-profit companies and its goal is to advance the speed of commercial adoption of novel and innovative therapies, diagnostics, devices, and technologies. The fund was launched with an initial $25 million investment from the American Cancer Society.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
